Recombinant subunit vaccine

Details Recombinant subunit vaccine Recombinant subunit vaccine

2000-08-18

2009-02-24

Campell, Bruce (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C530S300000, C530S350000, C424S196110, C424S197110, C424S278100

Reexamination Certificate

active

07494785

ABSTRACT:
A method is provided of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a cell which cell has been subjected to a stimulus which causes the induction of a heat shock response in said cells; and (b) recovering the antigenic polypeptide coupled to one or more hsps from said cell or the culture medium. Also provided are immunogenic compositions comprising a heat shock protein (hsp) derived from a non-mammalian eukaryote coupled to a heterologous antigenic polypeptide which composition is capable of inducing an immune response to said antigenic polypeptide in a human or animal.

REFERENCES:
patent: 5591632 (1997-01-01), O'Donnell et al.
patent: 5614381 (1997-03-01), Bromley et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5776465 (1998-07-01), O'Donnell et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/06828 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 98/12208 (1998-03-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 98/34641 (1998-08-01), None
patent: WO 98/34642 (1998-08-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/02670 (1999-01-01), None
patent: WO 99/07860 (1999-02-01), None
patent: WO 99/24049 (1999-05-01), None
patent: WO 99/29384 (1999-06-01), None
patent: WO 99/31257 (1999-06-01), None
patent: WO 99/42121 (1999-08-01), None
patent: WO 99/42472 (1999-08-01), None
patent: WO 00/10597 (2000-03-01), None
patent: WO 00/20606 (2000-04-01), None
Dirk Deregt, et al., Monoclonal antibodies to the E2 protein of a new genotype (type 2) of bovine viral diarrhea virus define thre antigenic domains involved in neutralization, Virus Research, vol. 57, pp. 171-181.
Roman et al. Immunology 1996 vol. 88 p. 487-492.
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Clamette Guerin priming,” Eur. J. Immunol., 22(6):1365-72 (1992) (abstract only).
Blachere et al., “Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity,” J. Exp. Med., 186(8):1315-22 (1997).
Bruschke et al., “An experimental multivalent bovine virus diarrhea virus E2 subunit vaccine and two experimental conventionally inactivated vaccines induce partial fetal protection in sheep,” Vaccine, 17(15-16):1983-91 (1999) (abstract only).
Lussow et al., “Mycobacterial heat-shock proteins as carrier molecules,” Eur. J. Immunol., 21(10):2297-302 (1991) (abstract only).
Perraut et al., “Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants,” Clin. Exp. Immunol., 93(3):382-6 (1993) (abstract only).
Przepiorka & Srivastava, “Heat shock protein-peptide complexes as immunotherapy for human cancer,” Mol. Med. Today, 4(11):478-84 (1998) (abstract only).
Robert et al., “Phylogenetic conservation of the molecular and immunological properties of the chaperones gp96 and hsp70,” Eur. J. Immunol., 31:186-95 (2001).
Srivastava & Udono, “Heat shock protein-peptide complexes in cancer immunotherapy,” Curr. Op Immunol., 6:728-32 (1994).
Srivastava, et al., “Heat shock proteins come of age: primitive functions acquire new roles in an adoptive world,” Immunity, 8:657-65 (1998).
Srivastava, “Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens,” Methods, 12(2):165-71 (1997) (abstract only).
International Search Report, International Application No. PCT/AU00/00988, International Filing Date Aug. 18, 2000, Applicant Minister for Agriculture, Minister for Land and Water Conservation for and on Behalf of the State of Newsouth Wales et al.
Rico et al., “Characterization of the immunostimulatory properties ofLeishmania infanttumHSP70 by fusion to theEscherichia colimaltose-binding protein in normal and nu
u BALB/c mice,”Infection and Immunity, 66(1):347-352 (1998).
Schirmbeck et al., “Truncated of chimeric endogenous protein antigens gain immunogenitcity for B cells by stress protein-facilitated expression,”European J. Immunol., 29(5): (1999).
Heikema, et al. “Generation of Heat Shock Protein-Based Vaccines by Intracellular Loading of GP96 with Antigenic Peptides,” Immunology Letters, 57(1-3):69-74 (1997).
Roman et al., “Synthetic Peptides Non-Covalently Bound to Bacterial HSP 70 Elicit Peptide-Specific T-Cell Responses in Vivo” Immunology, 88(4):487-492 (1996).
Supplementary European Search Report from EP 00954158.2 mailed Apr. 13, 2006.

Affiliated with

Also associated with

Rating

Recombinant subunit vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant subunit vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant subunit vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4131638